DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA) -

Mr. Rick Pauls, Chairman & CEO of DiaMedica, will present a corporate overview
of the Company at the Bloom Burton & Co. Healthcare Investor Conference on
Thursday June 21, 2012 at 3:30 pm ET at the Toronto Board of Trade, 1 First
Canadian Place, Toronto, Ontario. 


The Bloom Burton & Co. Healthcare Investor Conference brings together U.S.,
Canadian and European investors who are interested in the latest developments in
the Canadian healthcare sector. Attendees will have an opportunity to obtain
corporate updates from the premier Canadian public and private companies through
presentations and break-out Q&A sessions.


About Bloom Burton & Co.

Bloom Burton & Co. is Canada's largest and most active healthcare-specialized
investment banking group. The team of healthcare specialists merges scientific,
medical, clinical, intellectual property and commercial expertise with a strong
understanding of the capital markets, to advise and raise capital for private
and public companies. For more information, please visit www.bloomburton.com.


About DiaMedica

DiaMedica is a biopharmaceutical company focused on the discovery and
development of novel therapeutic compounds for diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, is a recombinant
human protein that represents a novel approach to treating Type 1 and Type 2
diabetes. In a Type 1 diabetes model, DM-199 halted the autoimmune attack on
beta cells by stimulating regulatory T-cells, and resulted in a 12-fold increase
in C-peptide levels. In Type 2 diabetes models, DM-199 treatment stimulated
proliferation of insulin producing beta cells, resulting in significant
improvement in glucose control.


DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment
for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model
resulted in significant improvement in blood glucose control and HbA1c levels
and also significant decreases in blood pressure and serum cholesterol.


Diamedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10
Cardiovascular/ Metabolic Projects to Watch".


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024